form_8-k.htm
UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
_______________
Form 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of
report (date of earliest event reported):
March
19, 2009
SCOLR
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-31982
|
|
91-1689591
|
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File No.)
|
|
(I.R.S.
Employer Identification No.)
|
19204
North Creek Parkway, Suite 100
Bothell,
WA 98011
(Address
of principal executive offices)
(425) 368-1050
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item 5.02
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers.
SCOLR Pharma,
Inc. reduced the size of its board of directors to six directors as part of its
efforts to decrease expenses. In connection with this decision, Dr. Reza Fassihi
and Gregory Weaver submitted resignations as directors on March 19, 2009 and
March 23, 2009, respectively. The resignations are effective as of March 31,
2009.
The Board of
Directors also updated membership of its board committees to include Messrs.
Lucas (Chairman), Caudill and Reich as members of the Audit Committee, Messrs.
Pines (Chairman), Reich and Lucas as members of the Nominating and Corporate
Governance Committee, and Messrs. Caudill (Chairman), Lucas and Pines as members
of the Compensation Committee effective March 20, 2009.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
SCOLR
PHARMA, INC.
|
|
Dated: March
24, 2009
|
By:
|
/s/
Bruce S. Morra
|
|
|
|
Bruce
S. Morra
President
and Chief Executive Officer
|
3